(Reuters) – Italian drug maker Recordati raised on Thursday its core profit (EBITDA) forecast to a range between 970 million euros and 1 billion euros ($1.01-$1.04 billion) with an around 37.5% EBITDA margin, from previous guidance at around 37%.
The pharmaceutical firm’s 2025 revenue forecast has also improved to a range of 2.60 billion euros to 2.67 billion euros from a previous indication of above 2.4 billion euros, as it sees a double-digit growth across all metrics, boosted by its rare disease products.
The Milan-based company posted a 12.5% jump in its full-year earnings before interest, tax, depreciation and amortisation to 865.8 million euros, while its revenue rose 12.4% to 2.34 billion euros.
Recordati said it will publish an updated three-year plan on April 28, along with medium-term financial targets.
($1 = 0.9602 euros)
(This story has been corrected to change the date of plan’s publication to April 28 in paragraph 4)
(Reporting by Romolo Tosiani in Gdansk; Editing by Tomasz Janowski)
